Progress in neglected disease drug discovery
Hopkins, A.L.; Wyatt, P.G.
Current Topics in Medicinal Chemistry 11(10): 1215
2011
ISSN/ISBN: 1568-0266 PMID: 21401510 Document Number: 653314
Document emailed within 1 workday
Related Documents
Silber, A.M.; Pereira, C.A.; Wrenger, C. 2014: Drug discovery for infectious agents causing neglected diseases Current Medicinal Chemistry 21(15): 1667Croft, S.L. 2007: Neglected diseases: progress in drug development Current Opinion in Investigational Drugs 8(2): 103-104
Ren, J.; Li, J.; Shi, F.; Wang, X.; He, J-Hua.; Xu, Y-Chun.; Zhang, N-Xia.; Xiong, B.; Shen, J-Kang. 2013: Progress in the fragment-based drug discovery Yao Xue Xue Bao 48(1): 14-24
Howard, J.M.; Stiles, H. 1994: Trauma--the disease that was neglected. Progress: past and that to be Journal of the Royal College of Surgeons of Edinburgh 39(6): 335-343
Williams, M. 2003: Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia Current Opinion in Investigational Drugs 4(1): 31-36
Kojima, H.; Okabe, T.; Nagano, T. 2013: Open innovation center for drug discovery: a research-supporting network for drug discovery Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 141(6): 327-332
Fujita, Y. 2013: Innovation by TaNeDS (Take a New challenge of Drug diScovery) collaborative drug discovery project Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 142(2): 89-95
Shen, Y. 2007: Discovery on Target 2007--CHI's Fifth Annual Conference. RNAi for Drug Discovery and Therapeutics IDrugs: the investigational drugs journal 10(12): 848-850
Young, S.S. 1999: Discovery 99: accelerate and improve the drug discovery process. 26-29 April 1999, San Diego, CA, USA IDrugs: the investigational drugs journal 2(7): 648-649
Kashyap, A.; Singh, P.Kumar.; Silakari, O. 2018: Counting on Fragment Based Drug Design Approach for Drug Discovery Current Topics in Medicinal Chemistry 18(27): 2284-2293
Alhenc-Gelas, Fçois.; Parmentier, L.; Bisagni, A. 2003: Pharmacogenetic and pharmacogenomic studies. Impact on drug discovery and drug development Therapie 58(3): 275-282
Emilien, G.; Maloteaux, J.M. 1998: Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities International Journal of Clinical Pharmacology and Therapeutics 36(4): 181-194
Armetti, L. 1999: Round table: The Italian Pharmacology Society and the drug industry: new processes in drug discovery and the contribution of universities Bollettino chimico farmaceutico 138(11): 596-598
Menear, K. 1998: Progress towards the discovery of orally active thrombin inhibitors Current Medicinal Chemistry 5(6): 457-468
Bittner, B.; Mountfield, R.J. 2002: Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters Current Opinion in Drug Discovery and Development 5(1): 59-71
Lee, K.H. 1987: Recent progress in the discovery and development of plant antitumor agents Gaoxiong Yi Xue Ke Xue Za Zhi 3(4): 234-250
Taube, A. 2002: Statistics must be seen and scrutinized! Fundamental to the progress of medical science--yet neglected in medical journals Lakartidningen 99(51-52): 5176-5179
Freeman, R.C.; Rodriguez, G.M.; French, J.F. 1996: Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue Aids Education and Prevention: Official Publication of the International Society for Aids Education 8(1): 58-71
1996: Redesigning drug discovery Nature 384(6604 Suppl): 1-5
Hadengue, A.; Moradpour, D. 2012: Alcoholic liver disease: another neglected disease? Revue Medicale Suisse 8(352): 1643-1644